Schizophrenia Research
Volume 123, Issue 1 , Pages 30-36 , October 2010

Randomized-controlled trials in people at ultra high risk of psychosis: A review of treatment effectiveness

  • Antonio Preti

      Affiliations

    • Centro Medico Genneruxi, Via Costantinopoli 42, 09129 Cagliari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 070 480922.
    • ,
  • Matteo Cella

      Affiliations

    • King's College London, Institute of Psychiatry, Department of Psychological Medicine, Weston Education Centre, Cutcombe Rd, London SE5 9RJ, United Kingdom
    • Tel.: +44 20 322 83191.

Received 8 March 2010 ,Revised 16 July 2010 ,Accepted 26 July 2010.

References 

  1. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry. 2010;67:146–154
  2. APA (American Psychiatric Association). DSM–IV. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association Press; 1994;
  3. Bechdolf A, Wagner M, Veith V, et al. A randomized controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophr. Res. 2006;86:S8
  4. Bechdolf A, Wagner M, Veith V, et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv. Psychiatry. 2007;1:71–78
  5. Bechdolf A, Wagner M, Ruhrmann S, et al. CBT in the early initial prodromal state: 24-months results. Schizophr. Res. 2008;102:S33
  6. Carson KP, Schriesheim CA, Kinicki AJ. The usefulness of the “fail-safe” statistic in meta-analysis. Educ. Psychol. Meas. 1990;50:233–243
  7. Cocchi A, Meneghelli A, Preti A. “Programma 2000”: celebrating ten years of activity of an Italian pilot program on early intervention in psychosis. Aust. N. Z. J. Psychiatry. 2008;42:1003–1012
  8. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being “at risk”. Schizophr. Res. 2005;73:173–184
  9. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk–benefit analysis. Schizophr. Res. 2010;120:16–22
  10. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry. 2007;68:546–557
  11. de Koning MB, Bloemen OJN, van Amelsvoort TAMJ, et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr. Scand. 2009;119:426–442
  12. Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J. Am. Stat. Ass. 2000;95:89–98
  13. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463
  14. Edwards J, McGorry PD. Implementing Early Intervention in Psychosis. A Guide to Establishing Early Psychosis Services. London, UK: Dunitz; 2002;
  15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  16. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis?. Lancet. 2007;370:1746–1748
  17. Gross G. The onset of schizophrenia. Schizophr. Res. 1997;28:187–198
  18. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum. Psychopharmacol. 2008;23(Suppl 1):15–26
  19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  20. Huber G, Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog. Med. 1989;80:646–652
  21. Huber G, Gross G, Schüttler R. Schizophrenie. Eine Verlaufsund sozialpsychiatrische Langzeitstudie. Berlin, Germany: Springer; 1979;
  22. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opin. Drug Discov. Dev. 2009;12:468–478
  23. Jenkins JH, Carpenter-Song EA. Awareness of stigma among persons with schizophrenia: marking the contexts of lived experience. J. Nerv. Ment. Dis. 2009;197:520–529
  24. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry. 2001;58:158–164
  25. Klosterkötter J, Ruhrmann S, Schultze-Lutter F, et al. The European prediction of psychosis study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4:161–167
  26. Larsen TK, Friis S, Haahr U, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr. Scand. 2001;103:323–334
  27. Lipsey MW, Wilson DB. Practical Meta-analysis. Sage Publications; 2001;
  28. Marshall M, Rathbone J. Early Intervention for Psychosis. Cochrane Database Syst. Rev. 2006;CD004718
  29. McGlashan TH, Zipursky RB, Perkins D, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis, I: study rationale and design. Schizophr. Res. 2003;61:7–18
  30. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry. 2006;163:790–799
  31. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am. J. Psychiatry. 2007;164:859–860
  32. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59:921–928
  33. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry. 2009;70:1206–1212
  34. Miller TJ, Mcglashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003;29:703–715
  35. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br. J. Psychiatry. 2004;185:291–297
  36. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 2007;33:682–687
  37. Nordentoft M, Thorup A, Petersen L, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006;83:29–40
  38. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?. Curr. Drug Saf. 2009;4:84–93
  39. Olsen KA, Rosenbaum B. Prospective investigation of the prodromal state of schizophrenia: review of studies. Acta Psychiatr. Scand. 2006;113:247–272
  40. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res. 2007;96:25–33
  41. Raballo A, Larøi F. Clinical staging: a new scenario for the treatment of psychosis. Lancet. 2009;374:365–367
  42. Raballo, A., Sæbye, D., Parnas, J., 2009. Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study. Schizophr. Bull. Jun 15. [Epub ahead of print]. doi:10.1093/schbul/sbp056.
  43. Rosenthal R. The “file drawer problem” and tolerance for null results. Psychol. Bull. 1979;86:638–641
  44. Ruhrmann S, Bechdolf A, Kühn KU, et al. LIPS study group Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br. J. Psychiatry. 2007;51(Suppl):S88–S95
  45. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill — advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr. Res. 2010;120:23–37
  46. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry. 2010;67:241–251
  47. Schulz, K.F., Altman, D.G., Moher, D., CONSORT Group, 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 152, 726–732.
  48. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. Am. Psychol. 1977;32:752–760
  49. WHO (World Health Organization). Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD–10). Geneve: WHO Press; 1992;
  50. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr. Res. 2010;120:42–48
  51. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996;22:353–370
  52. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr. Res. 2003;60:21–32
  53. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004;67:131–142
  54. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry. 2005;39:964–971
  55. Yung AR, Nelson B, Stanford C, et al. Validation of prodromal criteria to detect individuals at ultra high risk of psychosis: 2year follow-up. Schizophr. Res. 2008;105:10–17
  56. Yung AR, Nelson B, Thompson A, Wood SJ. The psychosis threshold in Ultra High Risk (prodromal) research: is it valid?. Schizophr. Res. 2010;120:1–6

PII: S0920-9964(10)01442-8

doi: 10.1016/j.schres.2010.07.026

Schizophrenia Research
Volume 123, Issue 1 , Pages 30-36 , October 2010

Article Tools